Sanli Pharmaceutical: Transfer of 16 drug marketing approval transfer payments of 2 million yuan

Sanli Pharmaceutical Announcement: The company has signed the “Drug Marketing Authorization Holder Transfer Agreement” with Guizhou Hanfang Pharmaceutical Co., Ltd., under which Hanfang Pharmaceutical will transfer the marketing authorizations for 16 drugs it holds and the related rights and interests to the company. Among them, Cisplatin Sodium Chloride Injection is the core product of this transfer. The total transfer consideration (including tax) is RMB 2 million. This transaction does not constitute a related-party transaction and does not constitute a major asset restructuring. Pursuant to the relevant provisions of the “Shanghai Stock Exchange Stock Listing Rules,” the “Articles of Association,” and other applicable regulations, the matters involved in this transaction do not require approval by the board of directors or the shareholders’ meeting. The change of the drug marketing authorization holder still requires approval from the drug regulatory authorities, and there is uncertainty as to whether the change can be completed successfully.